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Abstract 
The postnatal proliferation and maturation of insulin-secreting pancreatic β-cells are critical 
for glucose metabolism and disease development in adults. Elucidation of the molecular 
mechanisms underlying these events will be beneficial to direct the differentiation of stem 
cells into functional β-cells. Maturation of β-cells is accompanied by increased expression of 
MafA, an insulin gene transcription factor. Transcriptome analysis of MafA knockout islets 
revealed MafA is required for the expression of several molecules critical for β-cell function, 
including Glut2, ZnT8, Granuphilin, Vdr, Pcsk1 and Urocortin 3, as well as Prolactin 
receptor (Prlr) and its downstream target Cyclin D2 (Ccnd2). Inhibition of MafA expression 
in mouse islets or β-cell lines resulted in reduced expression of Prlr and Ccnd2, and MafA 
transactivated the Prlr promoter. Stimulation of β-cells by prolactin resulted in the 
phosphorylation and translocation of Stat5B and an increased nuclear pool of Ccnd2 via Prlr 
and Jak2. Consistent with these results, the loss of MafA resulted in impaired proliferation of 
β-cells at 4 weeks of age. These results suggest that MafA regulates the postnatal 
proliferation of β-cells via prolactin signaling.  
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Introduction 
Accumulating evidence suggests that postnatal organ development and maturation are 
critical for future health, especially with respect to metabolic disease [1]. Pancreatic β-cells 
vigorously proliferate postnatally to increase insulin secretion capacity [2], which is 
implicated in adult β-cell mass [3]. Although the compensatory growth of β-cell mass in 
insulin resistance has been intensively investigated [4], the signaling pathway that regulates 
postnatal proliferation of β-cells is less well known [5]. Uncovering this mechanism will 
elucidate how β-cell mass is regulated during development and how the insulin-expressing 
cells that differentiate from stem cells acquire the capacity to proliferate.  
During gestation, prolactin signaling is involved in the proliferation of β-cells. 
Generally, placental lactogen or prolactin binds to prolactin receptor (Prlr), which 
phosphorylates Janus kinase 2 (Jak2) and signal transducer and activator of transcription 5B 
(Stat5B) [5]. Phosphorylated Stat5B translocates into the nucleus and activates the 
transcription of its target genes by binding to GAS motifs, the Stat5 binding sequences [6]. 
The downstream targets of Prlr/Jak2/Stat5B signaling in β-cells include insulin, glucose 
transporter 2 (Glut2), glucokinase (Gck), tryptophan hydroxylase 1 (Tph1), cyclin D2 
(Ccnd2) and Prlr [6, 7]. In addition, prolactin signaling may also be involved in the 
proliferation of β-cells after birth, as Prlr knockout (KO) neonates have reduced β-cell mass 
[8].  
Maturation of β-cells occurs concurrently with the expression of v-maf 
musculoaponeurotic fibrosarcoma oncogene family protein A (MafA) [9], a transcription 
factor that regulates the expression of insulin via the C1-A2 elements of the insulin promoter 
[10]. In the pancreas, MafA is expressed exclusively in mature β-cells. Forced expression of 
MafA with Pdx1 and Ngn3 converts pancreatic acinar cells into insulin-secreting cells [11].  
MafA expression is reduced in the β-cell with compromised function [12]. In the islets of the 
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MafA knockout (KO) mice, the ratio of the β-cell mass to the -cell mass is normal at birth; 
however, this ratio is reduced during the neonatal period [13], suggesting that MafA may be 
involved in regulation of the postnatal β-cell mass. Thus, the role of MafA in postnatal 
proliferation of β-cells was investigated in this study.  
 
Materials and Methods 
Mice 
This study was carried out in strict accordance with the Fundamental Guidelines for 
Proper Conduct of Animal Experiment and Related Activities in Academic Research 
Institutions under the jurisdiction of Ministry of Health, Labour and Walfare. The protocol 
was approved by the Animal Care and Use Committee of the National Center for Global 
Health and Medicine (Permission Number: 13104). Islet isolation and pancreatic dissection 
were performed under deep anesthesia followed by cervical dislocation, and all efforts were 
made to minimize suffering. The generation of MafA KO mice was described previously [13]. 
Male mice were analyzed in this study. Mice were genotyped by NaOH extraction methods as 
described previously [14]. The primers used in this analysis are listed in Table S2 in File S1.  
 
Construction of Mouse Prolactin Reporter Luciferase Vectors 
A reporter vector containing the human Prlr promoter (hPrlr) was obtained from the 
Promoter Reporter GoClone Collection (Promega, Madison, WI). The mouse Prlr (mPrlr) 
luciferase reporter vectors mPrlrP-1, mPrlrP-2 and mPrlrP-3 were generated by amplifying 
2359 bp, 1304 bp and 608 bp fragments of the mPrlr promoter from high-quality mouse 
genomic DNA (Clontech) by PCR with the primers listed in Table S3 in File S1. An in-fusion 
cloning kit (Promega) was utilized to clone the amplified products into the pGL4.10 vector 
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(Clontech, Palo Alto, CA), which was digested with NheI and HindIII. The reporter vectors 
with deletions of the putative MafA binding regions, mPrlrP-5, mPrlrP-6, mPrlrP-8, mPrlrP-
9 and mPrlrP-11, were generated using the PrimeSTAR Mutagenesis Basal Kit (Takara Bio, 
Shiga, Japan); the reactions were performed using the primers listed in Table S3, and the 
pGL4.10-mPrlrP-1 reporter vector was used as a template. MafA binding sites were predicted 
with TRANSFAC (BIOBASE, Beverly, MA). The sequences of the reporter vectors were 
confirmed by sequencing with the universal RVprimer3.  
 
Transcriptome and Quantitative RT-PCR Analysis of Isolated Islets and Cultured Cells 
The islets were isolated from MafA KO or wild-type mice at 7 weeks of age using 
collagenase digestion as described previously [14]. Total RNA was extracted from the isolated 
islets or cultured cells using the QIAshredder and RNeasy Micro Kit (Qiagen Valencia, CA) 
following the manufacturer’s instructions. The concentration of purified RNA was measured 
by a NanoDrop ND 1000 Spectrophotometer (Thermo Scientific, Rockford, IL). The 
A260/280 of RNA from the wild-type and MafA KO islets were 1.94±0.07 and 1.86±0.04, 
respectively. RNA expression in the islets isolated from the MafA KO and wild-type mice was 
compared using the Mouse 430 2.0 Array (Affymetrix, Santa Clara, CA, USA, n=2) as 
described previously [15]. Samples for the analysis were prepared in accordance with the 
manufacturer’s protocol, and the results were analyzed using the DAVID 6.7 [16] and IPA 
programs (Ingenuity Systems, Redwood City, CA). Reverse transcription was performed 
using high-capacity cDNA reverse transcription kits (Applied Biosystems, Foster City, CA). 
Quantitative PCR amplification was performed using the TaqMan universal PCR master mix 
core reagent kit (Applied Biosystems) with the probes listed in Table S4 in File S1 and was 
analyzed using an ABI Prism 7900 (Applied Biosystems); Ct values were measured in 
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duplicate. mRNA was quantified by normalization to β-actin expression using the 2-ΔΔCt 
method. For analysis of the islets from the MafA KO mice and wild-type littermates, the 
expression of MafA was examined in all assays to confirm that MafA was absent in KO islets. 
The data are presented as the means ± S.E.M., and statistical significance was determined 
using a two-tailed unpaired Student's t-test. 
 
Cell Culture 
The rat β-cell line INS-1 [17], the mouse β-cell line MIN6 [18] and HeLa [19] cell 
lines were published previously. INS-1 cells were cultured in RPMI-1640 medium (Sigma, St. 
Louis, MO) supplemented with 10% (w/v) fetal bovine serum (FBS; Thermo Scientific), 1 
mM sodium pyruvate, 10 mM HEPES, 100 U/ml penicillin, 100 mg/ml streptomycin and 55 
µM β-mercaptoethanol (Life Technologies, Carlsbad, CA). MIN6 cells were cultured in 
Dulbecco's modified Eagle's medium (DMEM; Sigma) supplemented with 15% FBS, 
100 U/ml penicillin, 100 mg/ml streptomycin and 55 µM -mercaptoethanol. HeLa cells 
were cultured in DMEM supplemented with 10% FBS, 100 U/ml penicillin and 100 mg/ml 
streptomycin. All cell lines were cultured at 37°C with 5% CO2. 
For the prolactin stimulation experiments, INS-1 cells were transfected with siRNA 
against mouse MafA, rat MafA or rat Prlr (Silencer Select siRNA s233236, s172995 or 
Silencer siRNA 48147, respectively) or control siRNA (Life Technologies) using 
Lipofectamine 2000 (Life Technologies) according to the manufacturer’s protocol. The cells 
were plated in 6-well plates or 60 mm dishes, and the medium was changed 24 hours after 
transfection. The reduced expression of MafA or Prlr was confirmed by qRT-PCR 48 hours 
after transfection as described above. In parallel, the medium in the 60 mm dishes was 
changed to a defined serum-free medium consisting of RPMI-1640 medium supplemented 
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with 10 mM glucose (Sigma), 0.1% human serum albumin, 10 μg/ml human transferrin, 0.1 
nM triiodothyronine, 50 μM ethanolamine, 50 μM phosphoethanolamine (Wako, Osaka, 
Japan), 10 mM HEPES, 100 U/ml penicillin and 100 μg/ml streptomycin [20]. After 24 hours, 
mouse prolactin (R&D Systems, #1445-PL-050, Minneapolis, MN) was added at a final 
concentration of 1 μg/ml or at the indicated concentration, and the cells were incubated for 8 
hours with or without AG490 (Millipore, Billerica, MA). The cells were then evaluated by 
immunoblot analysis or immunofluorescence. 
 
Reporter Assay 
HeLa cells were transfected with the indicated reporter plasmids and the pCMV-β-gal 
plasmid (Promega), as an internal control, using Lipofectamine 2000 (Life Technologies) 
according to the manufacturer's protocol. The medium was changed 24 hours after 
transfection. At 48 hours after transfection, the firefly luciferase activity of the cells was 
analyzed using the luciferase assay system (Promega), and the β-gal activity was assessed as 
reported previously [14]. The data are presented as the means ± S.E.M., and statistical 
significance was determined using a two-tailed unpaired Student's t-test. 
 
Immunoblot Analysis 
INS-1 cells were harvested in PBS and sonicated in 200 μl of buffer containing 10 
mM Tris/HCl (pH 7.5), 150 mM NaCl, and 1% TX-100 supplemented with the protease 
inhibitor and phosphatase inhibitor cocktails (Nacalai Tesque, Kyoto, Japan). The lysates 
were centrifuged at 20,000 x g rpm for 2 minutes. The supernatant was analyzed by SDS-
PAGE followed by immunoblot analysis, as described previously [21]. For the nuclear 
fractionation, Subcellular Protein Fractionation Kit for Cultured Cells (Thermo Scientific) 
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was used following the manufacturer’s instructions. For immunoprecipitation, the supernatant 
was incubated with 20 μl of the indicated antibodies immobilized on 10 μl of protein G 
Sepharose 4 fast-flow beads (GE Healthcare, Fairfield, CT) for 3 hours at 4°C. After the 
beads were washed four times with 500 μl of buffer, containing 10 mM Tris/HCl (pH 7.5), 
150 mM NaCl, and 0.33% Triton X-100 supplemented with protease inhibitor and 
phosphatase inhibitor cocktails, the immunoprecipitates were subjected to SDS-PAGE and 
immunoblot analysis with the antibodies listed in Table S5 in File S1. Images were obtained 
with ChemiDoc XRS Plus (Biorad, Hercules, CA) and quantified using Image Lab 3.0 
(Biorad). The data are presented as the means ± S.E.M., and statistical significance was 
determined using a two-tailed unpaired Student's t-test. 
 
Immunofluorescence 
For immunofluorescence of cells, INS-1 cells were fixed with 4% (w/v) 
paraformaldehyde for 15 min and were permeabilized with 0.3% (w/v) Triton X-100 in PBS 
for 15 min. After blocking with PBS containing 10% (w/v) BSA for 30 min, the cells were 
incubated overnight with the primary antibodies (Table S5 in File S1) in PBS containing 3% 
(w/v) BSA. The cells were then washed with PBS and incubated with Texas red-conjugated 
anti-rabbit IgG and FITC-conjugated anti-mouse IgG (Jackson ImmunoResearch, West Grove, 
PA) in PBS containing 3% (w/v) BSA for 1 h, followed by washing with PBS and mounting 
with Mounting Medium containing 4',6-diamidino-2-phenylindole (DAPI) (Vector, 
Burlingame, CA).  
Immunostaining analyses of mice pancreatic sections were performed on paraffin-
embedded sections as described previously
 
[14]. The primary antibodies used in this study are 
listed in Table S5 in File S1. For amplification, biotinylated anti-mouse antibodies (Jackson 
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ImmunoResearch) were used at a 1:400 dilution, followed by incubation with streptavidin-
conjugated Alexa Fluor 488 (1:400) (Life Technologies). The secondary antibody was 
DyLight 594-conjugated anti-guinea pig IgG (Jackson ImmunoResearch). DAPI mounting 
medium (Vector) was used to label the nuclei.  
For both staining, immunofluorescent images were obtained using an Olympus FV-
1000 (Olympus) in confocal mode, and the acquired images were identically processed using 
Adobe Photoshop CS5.1. Quantification was performed using NIH ImageJ software. For the 
BrdU
+
/insulin
+
 cells from the MafA KO and wild-type pancreata, a total of 1706 and 1262 
insulin
+
 cells, respectively, were counted from 3 mice of each genotype. The data are 
presented as the means ± S.E.M., and statistical significance was determined using a two-
tailed unpaired Student's t-test. 
 
BrdU Incorporation Study 
A 10 mg/ml solution of 5’-bromo-2’ deoxyuridine (BrdU, Sigma) in PBS was filter-
sterilized and kept on ice. A dose of 100 mg BrdU/kg body weight was injected 
intraperitoneally into the mice, followed by ad libitum feeding for 24 hours. The mice were 
sacrificed, and BrdU incorporation in the pancreas was analyzed by immunofluorescence; a 
small section of the duodenum was used as a positive control for BrdU incorporation.  
 
Results 
MafA Is Involved in the Expression of Prolactin Receptor in β-Cells  
 To examine the role of MafA in β-cell, transcriptome analysis of MafA KO islets at 7 
weeks of age was performed. Several downregulated genes were detected, including Slc30a8 
(ZnT8), Vdr, Slc2a2 (Glut2), Pcsk1, Crystalline, Sytl4 (Granuphilin), Urocortin 3, Prlr and 
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Ccnd2 (Table S1 in File S1). Among the 9 molecules that were downregulated in both sets 
(Table 1), prolactin receptor (Prlr) was our primary focus because Prlr KO neonates have 
reduced β-cell mass [8]. The expression of Ccnd2, one of the downstream targets of prolactin 
signaling [22], was also markedly reduced in MafA KO islets (Table 1). Several genes that 
were downregulated in MafA KO islets, along with several molecules critical for β-cell 
function, were examined in mouse β-cell line MIN6 cells that were transfected with MafA 
siRNA and MIN6 cells that were transfected with control siRNA. While MafA was 
downregulated to 51.2±3.7% of its original expression (p<0.01), Prlr was significantly 
reduced to 78.6±1.5% relative to the controls (p<0.05; Fig. 1A). These results were further 
confirmed by analysis of the MafA KO islets by qRT-PCR. Prlr expression was reduced to 
31.5±4.9% in the MafA KO islets compared to the wild-type islets at 7 weeks of age (p<0.01; 
Fig. 1B). The expression of the prolactin signaling components Jak2 and Stat5A was not 
affected (p>0.05, respectively), while Stat5B expression was decreased (p<0.01). The 
expression of Ccnd2 was markedly reduced to 25.2±3.6% (p<0.01), while Ccnd1, Ccnd3, 
Cdkn1a, Cdkn1b and Cdkn1c were not impaired in MafA KO islets compared with wild-type 
islets (p>0.05, respectively; Fig. 1C). Reduced protein expression of Prlr and Ccnd2 was also 
detected in MafA KO islets (Fig. 1D and E). Quantification and statistical analyses showed 
that the expression of Prlr and Ccnd2 in KO islets was 24.8±15.9% and 50.3±15.9% of those 
in wild-type islets (p=0.04 and 0.05), respectively (Fig. 1F). These results suggest that MafA 
is directly or indirectly involved in the expression of Prlr and Ccnd2 in β-cells.  
In silico analysis detected six conserved MafA recognition elements (MAREs) 
between the transcription start site (TSS) and -3000 bp in the mouse Prlr promoter (Fig. 2B), 
and these sites were also preserved in the human and rat genes (data not shown). A luciferase 
reporter assay using the human and mouse Prlr (hPrlr and mPrlr, respectively) promoters 
clearly showed that overexpression of MafA transactivated both the hPrlr (p<0.01) and 
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mPrlr (p<0.05) promoters in HeLa cells (Fig. 2A and B). MafA activated the -2232 to +127 
mPrlr promoter fragment to a greater extent than the -1177 to +127 fragment (p=0.05) and 
the -481 to +127 fragment (p=0.06) (Fig. 2B). Moreover, the relative luciferase activity of 
various mPrlr promoter deletion constructs concomitant with forced expression of MafA 
revealed that the regions from -217 to -207 (IV; p<0.01) and from -2026 to -1409 (I to III; 
p<0.01) were involved in the MafA-mediated transcriptional activation of the mPrlr 
promoter (Fig. 2C). These results suggest that MafA transcriptionally regulates the expression 
of Prlr.  
 
Prolactin Signaling Regulates the Expression of Cyclin D2 in β-Cells 
To determine whether MafA and Prlr are involved in the expression of Ccnd2 in β-
cells, prolactin signaling was analyzed in rat β-cell line INS-1 cells, which were previously 
used to examine prolactin signaling [6, 7, 20, 23, 24]. The expression of MafA was 
41.5±5.8% of the control level with transfection of siRNA targeting MafA into INS-1 cells 
(p=0.09; Fig. 3A). Concomitant with the downregulation of MafA, the expression of Prlr, 
Ins1 and Ins2 was 84.8±7.0%, 83.7±7.3% and 68.5±8.4%, respectively, of the controls, but 
not statistically significant (p>0.05, respectively; Fig. 3A). Transfection of Prlr siRNA 
resulted in the reduction of Prlr expression to 55.7±2.3% of the control value (p=0.05) 
without reducing the expression of MafA, Ins1 or Ins2 (Fig. 3B). In INS-1 cells, stimulation 
with 1 µg/ml prolactin resulted in the tyrosine phosphorylation of Stat5B (Fig. 3C-F), and 
this effect on Stat5B phosphorylation was dose-dependent (Fig. 3G). Inhibition of Prlr 
expression with siRNA resulted in reduced phosphorylation of Stat5B but did not affect its 
total protein level (Fig. 3C-F). However, Inhibition of MafA expression with siRNA, resulting 
in 15.2% reduction in Prlr expression (Fig. 3A), did not significantly alter the tyrosine 
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phosphorylation of Stat5B in β-cells (Fig. 3C and D). Therefore, an siRNA targeting Prlr was 
used to examine the effect of reduced Prlr expression. 
In INS-1 cells, the majority of Stat5B was localized in the cytoplasm (Fig. 3H) and 
was translocated into the nucleus after prolactin stimulation (Fig. 3I). However, this 
prolactin-induced redistribution of Stat5B was impaired when Prlr expression was inhibited 
by siRNA (Fig. 3J and K). Inhibition of the prolactin-induced translocation of Stat5B was 
also observed after the addition of AG490, a Jak2 inhibitor (Fig. 3L-N). These results confirm 
the previous findings that prolactin-induced phosphorylation and nuclear translocation of 
Stat5B are mediated by Prlr and Jak2 [20]. Using these systems, the effect of prolactin 
signaling on the expression of Ccnd2 was examined. With upregulation in the 
phosphorylation of Stat5 in INS-1 cells, prolactin stimulation increased the amount of nuclear 
Ccnd2 (Fig. 3O). Quantitative analysis demonstrated that nuclear Ccnd2 protein was 
increased to 139.2±10.6% after prolactin stimulation (p=0.01). Ccnd2 protein relative to 
control Lamin A/C was 189.3±44.4% of the control level (p=0.09; Fig. 3P). We also 
examined the mRNA expression of Ccnd2 in INS-1 cells with siRNA targeting Prlr 
compared to those with control siRNA. mRNA expression of Prlr and Ccnd2 in INS-1 cells 
with siRNA targeting Prlr was 15.3±0.5% (p<0.01) and 84.9±2.9% (p=0.01) respectively, 
relative to the controls (Fig.3Q). These results verify the previous data [7, 24, 25], suggesting 
that prolactin signaling regulates the expression of Ccnd2 in β-cells.  
 
Reduced Proliferation of β-Cells in MafA KO Mice at 4 Weeks of Age 
Postnatal proliferation of β-cells is critical for the β-cell mass in adults [3]. Our above 
results prompted us to examine if the reduced expression of Prlr and Ccnd2 in the β-cells of 
MafA KO mice affected postnatal proliferation, as Ccnd2 KO neonates exhibit reduced 
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proliferation of β-cells and reduced β-cell mass [26]. The β-cell to -cell ratio in the islets of 
the MafA KO mice is also reduced after birth [13]. A BrdU incorporation assay was 
performed in MafA KO mice and their wild-type littermates at 4 weeks of age. BrdU-positive 
staining was observed in 0.35±0.0% of β-cells in MafA KO pancreas, while 1.57±0.48% of β-
cells in wild-type mice were BrdU-positive (p=0.06; Fig. 4A-C). These results suggested that 
the loss of MafA impaired the proliferation of β-cells in 4-week-old mice. Collectively, these 
results reveal a new role for MafA in the postnatal proliferation of β-cells through its 
regulation of prolactin signaling. 
 
Discussion 
This study described transcriptome analysis of the islets isolated from MafA KO mice. 
The results revealed the downstream candidates of MafA, and Prlr was a focus of this study. 
In the embryonic pancreas, Prlr is expressed primarily in acinar cells and ductal epithelium 
during early gestation. Later in gestation and in the postnatal period, Prlr is expressed 
predominantly in pancreatic islets [27], when MafA is expressed in β-cells [21]. The results 
from this study collectively suggest that MafA is critical for the expression of Prlr and that 
Prlr/Jak2/Stat5B signaling can induce the expression of Ccnd2 in β-cells. Consistent with 
these results, loss of MafA expression resulted in the impaired proliferation of postnatal β-
cells. Thus, prolactin signaling may play an important role in the proliferation of neonatal β-
cells under the control of MafA, in addition to its role in β-cell proliferation during gestation. 
Because the use of transformed β-cell lines may hamper the analysis of the promoter activity 
or the expression of Ccnd2 in detail, more analysis is needed to clarify the role of prolactin 
signaling on cell cycle in β-cells and to exclude the possibility that MafA directly activates 
the Ccnd2 promoter [28]. In addition to Prlr and the previously reported potential target genes 
of MafA/MafB, such as ZnT8 [29], Granuphilin [30] and Glut2 [13, 31], transcriptome 
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analysis of the MafA KO islets in this study showed the downregulation of Vdr, Pcsk1 and 
Urocortin 3, which are supposedly critical for β-cell function; however, the direct MafA 
binding sites in the promoters of these genes remain unknown. 
In rodents, prolactin and placental lactogen bind only to Prlr [8]. During gestation, the 
expression of Prlr in pancreas and the serum prolactin level increase [5, 32], although the 
action of prolactin is antagonized by progesterone [33]. β-Cell-specific expression of 
placental lactogen-I results in accelerated β-cell proliferation, increased β-cell mass and 
number and increased insulin production, leading to hypoglycemia and elevated plasma 
insulin [34]. In contrast, Prlr KO neonates have reduced β-cell mass [8]. During pregnancy, 
Prlr
+/-
 mice have reduced β-cell replication, but there is no increase in β-cell apoptosis, 
resulting in reduced β-cell mass. In Prlr+/- mice, impaired glucose clearance, decreased 
glucose-stimulated insulin release, higher post-prandial blood glucose, lower insulin levels 
and attenuated increases in islet density, -cell number and mass are also observed 
throughout pregnancy, but not in the absence of pregnancy [35]. These results suggest the 
important role of Prlr in -cell proliferation during pregnancy.  
At birth, maternal serum prolactin continues to rise to facilitate mammary gland 
function, while secretion of placental lactogen from the placenta peaks during mid-gestation 
[5, 34]. Thus, prolactin, which may originate from the mother’s feeding, may have a 
dominant effect on the neonatal proliferation of β-cells, not placental lactogen. An earlier 
study showed that prolactin and placental lactogen increase neonatal islet proliferation and 
insulin secretion [36]. Our results provide molecular evidence that Prlr is important for the 
postnatal proliferation of β-cells. Because β-cell replication in neonates plays a major role in 
β-cell mass in adult humans [3], the regulation of β-cell mass by prolactin signaling in 
postnatal pancreas may be implicated in an individual’s susceptibility to diabetes. 
Eto et al. 15 / 26 
The subcellular localization of Stat5 has been used to characterize the activation of 
the Jak2/Stat5 pathway by prolactin [20]. In β-cells, after exposure to prolactin, the 
redistribution of Stat5B from the cytoplasm to the nucleus was much higher than the 
redistribution of Stat5A, indicating that Stat5B plays a major role [23]. Stat5B binds to the 
GAS motif to induce the expression of its target genes [6], and our data suggested that Ccnd2 
can be a Stat5B target gene. Consistent with our data, dominant-negative Stat5 reduces 
mRNA and protein level of Ccnd2 and inhibits S-phase entry [24, 25]. Constitutively active 
form of Stat5B binds to the GAS motif in the Ccnd2 promoter, transactivates the Ccnd2 
promoter and induces the proliferation of β-cells [24]. Prolactin increases the mRNA 
expression of Ccnd2 in rat islets [7]. In vivo, Ccnd2 is essential for the postnatal expansion of 
β-cell mass and the compensatory increase in β-cell mass in response to insulin-resistant 
states [20, 37]. However, during gestation or in neonates, the regulation of Ccnd2 expression 
by the Prlr/Jak2/Stat5B pathway and its role in the proliferation of β-cells have not been 
confirmed in vivo [5]. Indeed, in pregnant Prlr
+/-
 mice, β-cell mass and Jak2 phosphorylation 
are decreased, but the expression of Ccnd2 is not changed [38], suggesting that more studies 
are necessary to investigate the precise role of prolactin signaling in the regulation of Ccnd2 
expression and β-cell proliferation in vivo. Another target of prolactin signaling that may be 
implicated in β-cell proliferation is Tph1, an enzyme to synthesize serotonin [39]. However, 
recent study showed no difference in β-cell proliferation between Tph1 KO mice and wild-
types during pregnancy even in the absence of serotonin [40], suggesting the importance of 
Ccnd2.  
In addition to its effect on proliferation, accumulating evidence suggests that prolactin 
signaling is also critical for β-cell function. Prolactin increases the expression of molecules 
such as insulin, Glut2, Gck, Tph1, FoxM1 and Prlr in rat islets or INS-1 cells [6, 7]. Prolactin 
and placental lactogen stimulate insulin release and increase insulin content in cultured adult 
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mouse islets and adult or newborn rat islets [41]. INS-1 cells constitutively expressing 
placental lactogen-II have increased Preproinsulin and Glut2 mRNA [42]. These results raise 
the possibility that prolactin signaling is involved in the functional maturation of β-cells from 
the immature insulin-expressing cells found in neonates. Prolactin increases the binding of 
Stat5 to the GAS motif of the Gck promoter and the Gck synthesis in β-cells even in the 
absence of glucose [6], suggesting its action can be independent of glucose. It would be 
interesting to examine if the β-cell-specific expression of Prlr or Ccnd2 improves both the 
proliferation and function of β-cells in MafA KO mice. Although Bcl2 and BclXL are also 
downstream targets of prolactin signaling, there is no increase in the apoptosis rate of β-cells 
in pregnant Prlr
+/-
 mice [35] and in MafA KO mice [43], suggesting that prolactin signaling 
does not play a major role in apoptosis of β-cells.  
Clinical studies have demonstrated that men and women with hyperprolactinemia 
have postprandial hyperinsulinemia and an exaggerated insulin secretory response to glucose 
and arginine [44, 45]. Thus, further studies are needed to elucidate the effects of prolactin and 
placental lactogen on the proliferation and functional maturation of human β-cells. Moreover, 
activation of prolactin signaling or inhibition of progesterone signaling [33, 46] in insulin-
expressing cells differentiated from human stem cells or endocrine precursor cells may 
enhance the proliferation and functional maturation of these cells.  
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Figure Legends 
Figure 1. Inhibition of MafA expression in β-cell lines or mouse islets resulted in reduced 
expression of Prlr and Ccnd2. 
(A) mRNA expression of the indicated molecules in MIN6 cells transfected with MafA siRNA 
relative to cells transfected with control siRNA. n=4 for each molecule, except n=3 for MafB. 
Black bars: molecules detected in the transcriptome of MafA KO islets; white bars: molecules 
involved in β-cell function. (B) qRT-PCR analysis of prolactin signaling components in MafA 
KO islets relative to wild-type islets. n=5 for Prlr; n=3 for Jak2, Stat5A and Stat5B. (C) qRT-
PCR analysis of molecules involved in the cell cycle in MafA KO islets relative to wild-type 
islets. n=4 for Ccnd1; n=5 for Ccnd2 and Ccnd3; n=3 for Cdkn1a, Cdkn1b and Cdkn1c. (D) 
Immunoblots of Prlr and actin in wild-type (WT) and MafA KO (KO) islets. n=3. (E) 
Immunoblots of Ccnd2 and actin in wild-type (WT) and MafA KO (KO) islets. n=3. (F) 
Quantification of the results of (D) and (E). The data represent the mean ± S.E.M. in (A), (B), 
(C) and (F), and representative results are shown in (D) and (E). Asterisks means p<0.05.  
 
Figure 2. Activation of the Prlr promoter by MafA. 
The effects of MafA expression on Prlr promoter activity were analyzed using HeLa cells. 
(A) Luciferase activity driven by the hPrlr promoter (from -890 to +103) in MafA-
overexpressing cells compared to control cells transfected with the control vector pcDNA3.1. 
n=8. (B) Luciferase activities driven by the mPrlr promoter constructs, including -2232 to 
+127 (mPrlrP-1), -1177 to +127 (mPrlrP-2) and -481 to +127 (mPrlrP-3), with or without 
overexpression of MafA, relative to the luciferase activity of mPrlrP-1 with control. n=5. Six 
putative MAREs were observed in the mPrlr promoter and are referred to as region I (from -
2026 to -2016), region II (from -1907 to -1897), region III (from -1723 to -1713), region IV 
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(from -217 to -207), region V (from -47 to -37) and region VI (from -12 to -2). TSS: 
transcription start site. (C) Luciferase activities of the mPrlrP-1 construct (-2232 to +127) 
with MafA compared to the luciferase activities of constructs with deletions in the following 
regions: region VI (from -12 to -2, mPlrlP-11), region V (from -47 to -37, mPlrlP-5), region 
IV (from -217 to -207, mPlrlP-6), from -800 to -535 (mPlrlP-9) or regions I to III (from -
2026 to -1409, mPlrlP-8). n=4. The data represent the mean ± S.E.M.  Asterisks means 
p<0.05. 
 
Figure 3. Regulation of Ccnd2 expression by prolactin signaling in β-cells.  
(A, B) mRNA expression of the indicated molecules in INS-1 cells transfected with siRNA 
targeting MafA (A) or Prlr (B) relative to INS-1 cells transfected with control siRNA. n=4 for 
both (A) and (B). (C-P) INS-1 cells were transfected with control siRNA or siRNA targeting 
Prlr (si-Prlr) or MafA (si-MafA). At 48 hours after transfection, the cells were cultured in 
defined serum-free medium for 24 hours for serum deprivation, followed by the addition of 
prolactin (PRL) or PBS as a control. (C, D) The immunoprecipitates obtained with anti-
Stat5B antibody from 1% TX-100 soluble fractions of INS-1 cells transfected with control si-
RNA, si-Prlr or si-MafA, and with or without PRL stimulation were immunoblotted with 
either anti-Stat5B (C) or anti-phosphotyrosine antibody (D). n=3. (E, F) 1% TX-100 soluble 
fractions of INS-1 cell lysates were immunoblotted with either anti-Stat5B (E) or anti-
phosphorylated Stat5 antibody (F). n=3. (G) Dose-dependent effects of PRL on the 
phosphorylation of Stat5. n=2. (H-K) Localization of Stat5B (red), β-catenin (green) and 
nuclei, which were counterstained with DAPI (blue), in INS-1 cells that were transfected or 
not with si-Prlr and stimulated or not with PRL. n=3. (L-N) Localization of Stat5B (red), β-
catenin (green) and nuclei, which were counterstained with DAPI (blue), in INS-1 cells with 
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or without PRL stimulation and with or without exposure to AG490, a Jak2 inhibitor. n=3. (O, 
P) The amount of phosphorylated Stat5, Ccnd2 and Lamin A/C (control) in the nuclear 
fraction of INS-1 cells with (w/) or without (w/o) PRL stimulation after serum deprivation (O), 
and quantification of the results (P). n=4. (Q) mRNA expression of the indicated molecules in 
INS-1 cells transfected with siRNA targeting Prlr relative to INS-1 cells transfected with 
control siRNA. n=3 for each molecule. The data represent the mean ± S.E.M. in (A), (B), (P) 
and (Q), and representative results are shown in (C-O). Asterisks means p<0.05. 
 
Figure 4. Impaired proliferation of β-cells in MafA KO mice. 
(A, B) Representative islets of MafA KO mice and their wild-type littermates 24 hours after 
the injection of BrdU (100 mg BrdU/kg body weight). BrdU (green), insulin (red) and DAPI 
(blue). (C) Quantification of the BrdU
+
 cells among the insulin
+
 cells. In total, 1706 insulin
+
 
cells were counted in the MafA KO pancreas, and 1262 insulin
+
 cells were counted in the 
wild-type pancreas. The proliferation of β-cells in MafA KO mice was impaired. n=3. The 
data represent the mean ± S.E.M. Bar, 20 µm. 
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Table 1. Genes that were downregulated in MafA KO islets in both transcriptome 
datasets  
Probe set Gene Gene symbol 
Fold increase 
(WT/KO) 
Set 1 Set 2 
1418783_at 
Transient receptor potential cation channel, subfamily M, member 5 Trpm5 
14.9 26.0 
1443413_s_at n.d. 21.1 
1449224_at n.d. 9.9 
1434354_at Monoamine oxidase B Maob 8.6 7.0 
1417336_a_at Synaptotagmin-like 4 / Granuphilin Sytl4 8.0 14. 9 
1422837_at Sciellin Scel 4.9 2.1 
1441102_at 
Prolactin receptor Prlr 
4.0 2.6 
1448556_at 3.0 2.3 
1437397_at 2.6 2.3 
1425853_s_at 2.1 2.6 
1454632_at 
RIKEN cDNA 6330442E10 gene Tmem229B 
3.7 4.0 
1457254_x_at 4.0 6.1 
1424291_at Similar to nucleoporin 93; nucleoporin 93 Nup93 4.0 2.1 
1416123_at 
Cyclin D2 Ccnd2 
3.5 4.3 
1448229_s_at 2.8 3.7 
1430127_a_at 2.6 2.8 
1455956_x_at 2.5 3.3 
1416124_at n.d. 2.6 
1416122_at 2.1 2.5 
1434745_at 2.0 2.3 
1423640_at Synaptoporin Synpr 3.5 4.3 
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